PubRank

Cheryl H Baker

Author PubWeight™ 39.23‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006 2.07
2 Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006 1.83
3 Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 2007 1.64
4 Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 2006 1.51
5 Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res 2005 1.34
6 Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res 2005 1.34
7 Cerium oxide nanoparticles protect gastrointestinal epithelium from radiation-induced damage by reduction of reactive oxygen species and upregulation of superoxide dismutase 2. Nanomedicine 2010 1.34
8 Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005 1.33
9 Protection from radiation-induced pneumonitis using cerium oxide nanoparticles. Nanomedicine 2009 1.22
10 Bcl-B expression in human epithelial and nonepithelial malignancies. Clin Cancer Res 2008 1.16
11 c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas 2005 1.14
12 AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther 2005 1.13
13 Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol 2010 1.04
14 Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 2002 1.02
15 Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. Cancer Res 2006 1.02
16 Quantitative and qualitative in vivo angiogenesis assay. Int J Oncol 2002 1.02
17 Sensitization of pancreatic cancer cells to radiation by cerium oxide nanoparticle-induced ROS production. Nanomedicine 2012 1.01
18 Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Mol Cancer Ther 2007 1.00
19 Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 2009 0.99
20 Multicolored redox active upconverter cerium oxide nanoparticle for bio-imaging and therapeutics. Chem Commun (Camb) 2010 0.96
21 Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 2009 0.94
22 Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin Cancer Res 2003 0.92
23 Bioluminescence imaging correlates with tumor progression in an orthotopic mouse model of lung cancer. Surg Oncol 2010 0.91
24 Angiogenesis: an update and potential drug approaches (review). Int J Oncol 2010 0.91
25 Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol 2011 0.89
26 Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Clin Cancer Res 2002 0.87
27 A facile nanoparticle immunoassay for cancer biomarker discovery. J Nanobiotechnology 2011 0.86
28 Harnessing nanoparticles to improve toxicity after head and neck radiation. Nanomedicine 2012 0.86
29 A metastatic colon cancer model using nonoperative transanal rectal injection. Surg Endosc 2009 0.85
30 Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis. Clin Cancer Res 2009 0.85
31 Phosphate ester hydrolysis of biologically relevant molecules by cerium oxide nanoparticles. Nanomedicine 2010 0.84
32 Novel murine model for colon cancer: non-operative trans-anal rectal injection. J Surg Res 2008 0.83
33 Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation. J Neurosurg 2008 0.81
34 Therapeutic applications of NSAIDS in cancer: special emphasis on tolfenamic acid. Front Biosci (Schol Ed) 2011 0.81
35 MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy. Mol Med 2012 0.81
36 Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells. Mol Carcinog 2010 0.78
37 Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. Invest New Drugs 2011 0.78